
How a Drugmaker Profited by Slow-Walking a Promising HIV Therapy
In 2004, Gilead Sciences decided to stop pursuing a new HIV drug. The public explanation was that it wasn’t sufficiently different from an existing treatment...
In 2004, Gilead Sciences decided to stop pursuing a new HIV drug. The public explanation was that it wasn’t sufficiently different from an existing treatment...
A federal jury has found that the federal government did not have an ownership claim to lucrative drugs to prevent HIV that are sold by...
An analysis led by researchers in Britain found that a year’s supply of the drug, Trikafta, could be manufactured at an estimated cost of just...
In 2016, a blockbuster drug called Humira was poised to become a lot less valuable.
Ascension spent years reducing its staffing levels in an effort to improve profitability, even though it's a nonprofit with nearly $18 billion of cash reserves.
Democrats are on the verge of passing a broad budget bill that would lower drug costs and deliver President Joe Biden a political victory that...